ArticleWorld journal of gastroenterology2012
Serum pepsinogen II is a better diagnostic marker in gastric cancer.
Article in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Explores the Relationship Between Serum Pepsinogen Levels and Gastric Mucosal Changes in Relation toJournal of inflammation research · 2026Article
- Diagnostic Value of Serum Pepsinogen andGastroenterology research and practice · 2026Article
- Intraoperative plasma proteomic changes in cardiac surgery: In search of biomarkers of post-operative delirium.Proteomics. Clinical applications · 2023Article
- Risk factors for gastric cancer and related serological levels in Fujian, China: hospital-based case-control study.BMJ open · 2020Article
- Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Article
- miR-539-3P inhibits proliferation and invasion of gastric cancer cells by targeting CTBP1.International journal of clinical and experimental pathology · 2019Article
- Gastric Cancer Screening by Combined Determination of SerumChinese medical journal · 2018Review
- Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer.Cancer medicine · 2018Article
- Pepsinogen C expression, regulation and its relationship with cancer.Cancer cell international · 2017Review
- CD24 genetic variants contribute to overall survival in patients with gastric cancer.World journal of gastroenterology · 2016Observational
- Serum biomarker panels for diagnosis of gastric cancer.OncoTargets and therapy · 2016Article
- A Novel Electrochemical Microfluidic Chip Combined with Multiple Biomarkers for Early Diagnosis of Gastric Cancer.Nanoscale research letters · 2015Article
- Geographical distribution of the incidence of gastric cancer in Bhutan.World journal of gastroenterology · 2015Article
- Characterization of differentially expressed genes involved in pathways associated with gastric cancer.PloS one · 2015Article
- CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach.BMC gastroenterology · 2014Article
- DNA methyltransferase3a expression is an independent poor prognostic indicator in gastric cancer.World journal of gastroenterology · 2014Article
- Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis.World journal of gastroenterology · 2014Article
- Monitoring of peri-distal gastrectomy carbohydrate antigen 19-9 level in gastric juice and its significance.International journal of clinical and experimental medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate screening makers for gastric cancer, we assessed the association between gastric cancer and serum pepsinogens (PGs).
methodsThe subjects comprised 450 patients with gastric cancer, 111 individuals with gastric atrophy, and 961 healthy controls. Serum anti-Helicobacter pylori (H. pylori) immunoglobulin G (IgG), PGI and PG II were detected by enzyme-linked immunosorbent assay. Gastric atrophy and gastric cancer were diagnosed by endoscopy and histopathological examinations. Odds ratios and 95%CIs were calculated using multivariate logistic regression.
resultsRates of H. pylori infection remained high in Northeastern China. Rates of H. pylori IgG positivity were greater in the gastric cancer and gastric atrophy groups compared to the control group (69.1% and 75.7% vs 49.7%, P < 0.001). Higher levels of PG II (15.9 μg/L and 13.9 μg/L vs 11.5 μg/L, P < 0.001) and lower PGI/PG II ratio (5.4 and 4.6 vs 8.4, P < 0.001) were found in patients with gastric cancer or gastric atrophy compared to healthy controls, whereas no correlation was found between the plasma PGI concentration and risk of gastric cancer (P = 0.537). In addition, multivariate logistic analysis indicated that H. pylori infection and atrophic gastritis were independent risk factors for gastric cancer. Lower plasma PGI/PG II ratio was associated with higher risks of atrophy and gastric cancer. Furthermore, plasma PG II level significantly correlated with H. pylori-infected gastric cancer.
conclusionSerum PG II concentration and PGI/PG II ratio are potential biomarkers for H. pylori-infected gastric disease. PG II is independently associated with risk of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.